Persistent neuropathy after treatment with cisplatin and oxaliplatin

被引:87
作者
Brouwers, Elke E. M. [1 ]
Huitema, Alwin D. R. [1 ]
Boogerd, Willem [1 ,2 ]
Beijnen, Jos H. [1 ,3 ]
Schellens, Jan H. M. [2 ,3 ]
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol & Neurooncol, NL-1066 CX Amsterdam, Netherlands
[3] Univ Utrecht, Sect Drug Toxicol, Div Biomed Anal, Dept Pharmaceut Sci,Beta Fac, NL-3508 TB Utrecht, Netherlands
关键词
INDUCED PERIPHERAL NEUROPATHY; TESTICULAR CANCER SURVIVORS; LONG-TERM TOXICITY; OVARIAN-CANCER; PERCEPTION THRESHOLDS; GENETIC-POLYMORPHISM; NEUROTOXICITY; CHEMOTHERAPY; PLATINUM; QUESTIONNAIRE;
D O I
10.1080/02841860902806609
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The aims of the current explorative study were to assess persistent neuropathy in 45 patients up to 6 years after treatment with cisplatin or oxaliplatin and to determine the most adequate method to evaluate neuropathy. Furthermore, the effect of possible determinants on persistent neuropathy was investigated. Material and methods. The assessment of neuropathy was performed using a questionnaire, by neurological tests, and by vibration threshold (VT) measurements. Because VT determination gives the most objective information, VT measurements were used for further analyses. Results and discussion. The analyses revealed that neuropathy of the hands was related to follow-up time, with an observed recovery half-life of 6.8 (+/-3.1) years. No significant reversibility of neuropathy of the feet within the observation period could be demonstrated. For cisplatin, the severity of neuropathy was related to the cumulative dose and sodium thiosulfate use. Oxaliplatin induced neuropathy did not appear to be related to the dose within the studied dose range. No relationship with platinum levels, renal function, glutathione transferase genotypes, diabetes mellitus, alcohol use, or co-medication could be demonstrated. This study was performed as an explorative study and the issues discussed need to be investigated further.
引用
收藏
页码:832 / 841
页数:10
相关论文
共 44 条
[41]   PREVENTION OF CISPLATIN NEUROTOXICITY WITH AN ACTH(4-9) ANALOG IN PATIENTS WITH OVARIAN-CANCER [J].
VANDERHOOP, RG ;
VECHT, CJ ;
VANDERBURG, MEL ;
ELDERSON, A ;
BOOGERD, W ;
HEIMANS, JJ ;
VRIES, EP ;
VANHOUWELINGEN, JC ;
JENNEKENS, FGI ;
GISPEN, WH ;
NEIJT, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (02) :89-94
[42]  
VANDERHOOP RG, 1990, CANCER-AM CANCER SOC, V66, P1697, DOI 10.1002/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO
[43]  
2-G
[44]   Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms [J].
Zhang, K ;
Chew, M ;
Yang, EB ;
Wong, KP ;
Mack, P .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :837-843